Veru Kicks Off Phase 2b Trial for Enobosarm-Semaglutide Weight Loss Therapy
VERU sits 16% above its 52-week low of $2.1.
Summary
Veru Inc. announced the enrollment of the first patient in its Phase 2b PLATEAU clinical trial, which will assess the combination of enobosarm and semaglutide for "high quality weight loss" in older obese patients. This study aims to preserve lean mass and physical function while enhancing fat loss, potentially differentiating it in the competitive GLP-1 market. For a company that recently issued a "going concern" warning and completed a dilutive offering, this operational milestone represents crucial progress in its clinical pipeline. The advancement of enobosarm, previously noted for positive updates, is vital for investor confidence. Key catalysts to watch include the interim analysis expected in Q1 2027 and final topline data in Q4 2027.
At the time of this announcement, VERU was trading at $2.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.6M. The 52-week trading range was $2.10 to $7.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.